• FREE

    Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly–Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

    Metastatic Melanoma: Novel Approaches discusses the epidemiology, causes, clinical features, pathogenesis and immunotherapy in the treatment of metastatic melanoma.

    By the end of Metastatic Melanoma: Novel Approaches, you will be able to:
    • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
    • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe emerging (investigational) therapies for metastatic melanoma
    • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

    Target Audience:
    Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.

    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 4, 2017
    • Expiration of CME credit: December 4, 2019
  • FREE

    Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy

    The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients.

    By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
    • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
    • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
    Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
    • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

    Target Audience:
    Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 17, 2017
    • Expiration of CME credit: November 17, 2019
  • FREE

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics consists of a single presentation with discussion featuring Drs. Bradley J. Monk, MD and Robert L. Coleman, MD.

    At the conclusion of Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics, you will be able to:
    • Appraise the pathophysiology of ovarian cancer and their associated mutations, including germline and somatic BRCA mutations and other DNA repair deficiencies such as loss of heterozygosity
    • Evaluate the safety and efficacy data of PARP inhibitors
    • Use the latest diagnostic tools and genetic testing to identify patients who would benefit from PARP inhibitor therapy

    Target Audience:
    This program is intended for Medical and gynecologic oncologists, oncology nurses, nurse practitioners, pharmacists, and other health care professionals, including gynecologists, primary care physicians, physicians-in-training, and physician assistants involved in and/or interested in the management of patients with ovarian cancer.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: October 20, 2017
    • Expiration of CME credit: April 20, 2018
  • FREE

    Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies

    Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).

    By the end of Advances in Treating Metastatic Colorectal Cancer (CRC), you will be better able to:
    • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
    • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
    • Describe the challenges and barriers to care associated with treating patients with mCRC

    In order to receive credit from ScientiaCME, you must first establish a username and password.

    Target Audience:
    Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 19, 2017
    • Expiration of CME credit: October 19, 2019
  • FREE

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

    By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

    Target Audience:
    Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 02, 2017
    • Expiration of CME credit: November 02, 2019
  • FREE

    New Horizons in Personalized Care for Metastatic Bladder Cancer

    New Horizons in Personalized Care for Metastatic Bladder Cancer consists of a single lecture, New Horizons in Personalized Care for Metastatic Bladder Cancer with discussion by Matthew I. Milowsky, MD and Matthew Galsky, MD.

    After viewing New Horizons in Personalized Care for Metastatic Bladder Cancer, you will be better able to:
    • Evaluate the role of new targeted and immune-based agents in the first- and second-line metastatic settings, and how they can be integrated into practice
    • Apply strategies and tools that enhance patient-clinician communication and shared decision making processes

    Target Audiences:
    This program is intended for Medical/genitourinary oncologists, urologists, surgeons, radiologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with bladder cancer.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Albert Einstein College of Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: August 11, 2017
    • Expiration of CME credit: February 11, 2018
  • FREE

    Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions

    Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions consists of two lectures with discussion, Effective Management Strategies for Head and Neck Cancer and The New Paradigm of Immunotherapy for Head and Neck Cancer, both with Robert I. Haddad, MD and Jared Weiss, MD.

    After viewing Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions, you will be better able to :
    • Assess the safety and efficacy of available and emerging multimodal regimens, including immunotherapy, for patients with head and neck cancer
    • Utilize strategies to optimally sequence available regimens for the therapeutic management of head and neck cancer
    • Evaluate the latest clinical efficacy and safety data on the use of immune checkpoint inhibitors in head and neck cancer
    • Examine anticipated adverse events related with immune checkpoint inhibitors in head and neck cancer

    Target Audience:
    This program is intended for medical and radiation oncologists, head and neck surgeons, otolaryngologists, ear, nose and throat (ENT) specialists, and other health care professionals (primary care providers, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with head and neck cancer.

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: Postgraduate Institute for Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: August 24, 2017
    • Expiration of CME credit: February 24, 2018
  • FREE

    Emerging Therapies for Relapsed/Refractory Multiple Myeloma

    Emerging Therapies for Relapsed/Refractory Multiple Myeloma consists of a single lecture, Emerging Therapies for Relapsed/Refractory Multiple Myeloma, with discussion by Ravi Vij, MD, MBA and David Dingli, MD, PhD.

    After viewing Emerging Therapies for Relapsed/Refractory Multiple Myeloma, you will be better able to :
    • Identify disease-related, patient-related, and cytogenetic factors that shape treatment decisions for the management of relapsed/refractory MM
    • Examine safety and efficacy data of emerging strategies for patients with MM who have received prior lines of therapies including proteasome inhibitors and immunomodulatory agents
    • Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
    • Discuss the therapeutic implications of combination regimens involving emerging agents with currently available treatment option

    Target Audience:
    This program is intended for US-based hematologist-oncologists, oncologists, oncology nurses, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients with multiple myeloma.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: University of Nebraska Medical Center, Center for Continuing Education
    • Format: On-Demand Online, Online Video
    • Material last updated: September 13, 2017
    • Expiration of CME credit: March 13, 2018
  • FREE

    Metastatic Melanoma: Updates from ASCO 2017

    Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges.

    Metastatic Melanoma: Updates from ASCO 2017 summarizes major findings from ASCO 2017 related to Metastatic Melanoma, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice

    After reviewing Metastatic Melanoma: Updates from ASCO 2017 you will be able to:
    • Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.

    Target Audience:
    Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 19 2017
    • Expiration of CME credit: September 19 2019
  • FREE

    Risky Business: Diagnosing and Treating Invasive Fungal Infections

    Risky Business: Diagnosing and Treating Invasive Fungal Infections consists of 3 brief lectures on the diagnosis and treatment of invasive fungal infection:

    After completing Risky Business: Diagnosing and Treating Invasive Fungal Infections, you should be better able to:
    • Describe the epidemiology and burden of invasive fungal infections in patients who are immunocompromised and/or Immunosuppressed.
    • Incorporate the latest diagnostic techniques for invasive fungal infections to ensure that the appropriate therapy can be initiated in a timely manner.
    • Integrate the latest evidence-based treatment guidelines and clinical data pertaining to the efficacy, safety, and prophylactic use of antifungal agents to optimize the management of invasive fungal infections.

    Target Audience:
    Hematologist-oncologists, medical oncologists, transplant surgeons, critical care surgeons, critical care pulmonologists, and other health care professionals involved in the treatment of patients with or at risk for invasive fungal infections.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Vindico Medical Education
    • Format: On-Demand Online, Online Video
    • Material last updated: April 18, 2017
    • Expiration of CME credit: April 17, 2018